WO2009151346A1 - A method for determining bacterial antibiotic resistance or bacterial susceptibility, a diagnostic kit for the detection of the antibiotic resistance and use of such diagnostic kit - Google Patents
A method for determining bacterial antibiotic resistance or bacterial susceptibility, a diagnostic kit for the detection of the antibiotic resistance and use of such diagnostic kit Download PDFInfo
- Publication number
- WO2009151346A1 WO2009151346A1 PCT/PL2009/000066 PL2009000066W WO2009151346A1 WO 2009151346 A1 WO2009151346 A1 WO 2009151346A1 PL 2009000066 W PL2009000066 W PL 2009000066W WO 2009151346 A1 WO2009151346 A1 WO 2009151346A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibiotic
- detection
- antibiotic resistance
- test
- resistance
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 158
- 238000001514 detection method Methods 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 52
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 26
- 238000009007 Diagnostic Kit Methods 0.000 title claims abstract description 12
- 238000012125 lateral flow test Methods 0.000 claims abstract description 34
- 238000003556 assay Methods 0.000 claims abstract description 31
- 241000894006 Bacteria Species 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 239000002207 metabolite Substances 0.000 claims abstract description 14
- 206010059866 Drug resistance Diseases 0.000 claims abstract description 9
- 210000002700 urine Anatomy 0.000 claims description 36
- 239000003242 anti bacterial agent Substances 0.000 claims description 35
- 229940088710 antibiotic agent Drugs 0.000 claims description 25
- 238000012216 screening Methods 0.000 claims description 19
- 210000001124 body fluid Anatomy 0.000 claims description 14
- 239000010839 body fluid Substances 0.000 claims description 14
- 239000013060 biological fluid Substances 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 6
- 150000003952 β-lactams Chemical class 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 4
- 230000001524 infective effect Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 abstract description 63
- 230000000845 anti-microbial effect Effects 0.000 abstract description 4
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 4
- 238000005259 measurement Methods 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 description 23
- 206010040047 Sepsis Diseases 0.000 description 15
- 230000002458 infectious effect Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 229930195708 Penicillin V Natural products 0.000 description 11
- 229960003022 amoxicillin Drugs 0.000 description 11
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 11
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 11
- 229940056367 penicillin v Drugs 0.000 description 11
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 11
- 229930182555 Penicillin Natural products 0.000 description 10
- 208000004396 mastitis Diseases 0.000 description 10
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 7
- 102000006635 beta-lactamase Human genes 0.000 description 7
- 229940049954 penicillin Drugs 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000002132 β-lactam antibiotic Substances 0.000 description 7
- 229940124586 β-lactam antibiotics Drugs 0.000 description 7
- 241000194017 Streptococcus Species 0.000 description 6
- 229960001668 cefuroxime Drugs 0.000 description 6
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 6
- 229940106164 cephalexin Drugs 0.000 description 6
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108020004256 Beta-lactamase Proteins 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- -1 Cefonicide Chemical compound 0.000 description 5
- 239000012156 elution solvent Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 241000186779 Listeria monocytogenes Species 0.000 description 4
- 108010087702 Penicillinase Proteins 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010018612 Gonorrhoea Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 241001148470 aerobic bacillus Species 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000000721 bacterilogical effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 229960004755 ceftriaxone Drugs 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 150000002960 penicillins Chemical class 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 229940086793 amoxicillin 250 mg Drugs 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 125000003460 beta-lactamyl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960004682 cefoperazone Drugs 0.000 description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 2
- 229960004261 cefotaxime Drugs 0.000 description 2
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960003326 cloxacillin Drugs 0.000 description 2
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 description 2
- 229950009506 penicillinase Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 208000012313 wound discharge Diseases 0.000 description 2
- JETQIUPBHQNHNZ-NJBDSQKTSA-N (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2r)-2-phenyl-2-sulfoacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound C1([C@H](C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)S(O)(=O)=O)=CC=CC=C1 JETQIUPBHQNHNZ-NJBDSQKTSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- MQTOSJVFKKJCRP-HHZDEWPHSA-N Azythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@H]([C@@]([C@H](O)[C@H](C)N(C)C[C@@H](C)C[C@](C)(O)[C@@H](O[C@@H]2[C@H]([C@@H](C[C@H](C)O2)N(C)C)O)[C@@H]1C)(C)O)CC)[C@@H]1C[C@](C)(OC)[C@H](O)[C@@H](C)O1 MQTOSJVFKKJCRP-HHZDEWPHSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 208000019462 Occupational injury Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108700020474 Penicillin-Binding Proteins Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 102100022399 Ribosome biogenesis protein NOP53 Human genes 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 229940024554 amdinocillin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960004328 azidocillin Drugs 0.000 description 1
- ODFHGIPNGIAMDK-NJBDSQKTSA-N azidocillin Chemical compound C1([C@@H](N=[N+]=[N-])C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 ODFHGIPNGIAMDK-NJBDSQKTSA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002536 benzathine benzylpenicillin Drugs 0.000 description 1
- 229940095744 benzathine phenoxymethylpenicillin Drugs 0.000 description 1
- BVGLIYRKPOITBQ-ANPZCEIESA-N benzylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960000717 carindacillin Drugs 0.000 description 1
- JIRBAUWICKGBFE-MNRDOXJOSA-N carindacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 JIRBAUWICKGBFE-MNRDOXJOSA-N 0.000 description 1
- 229960003972 cefacetrile Drugs 0.000 description 1
- RRYMAQUWDLIUPV-BXKDBHETSA-N cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229960002420 cefatrizine Drugs 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 229960005312 cefazedone Drugs 0.000 description 1
- VTLCNEGVSVJLDN-MLGOLLRUSA-N cefazedone Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3C=C(Cl)C(=O)C(Cl)=C3)[C@H]2SC1 VTLCNEGVSVJLDN-MLGOLLRUSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960004069 cefditoren Drugs 0.000 description 1
- KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960001958 cefodizime Drugs 0.000 description 1
- XDZKBRJLTGRPSS-BGZQYGJUSA-N cefodizime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 description 1
- 229960004292 ceforanide Drugs 0.000 description 1
- SLAYUXIURFNXPG-CRAIPNDOSA-N ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960001242 cefotiam Drugs 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960005446 cefpiramide Drugs 0.000 description 1
- PWAUCHMQEXVFJR-PMAPCBKXSA-N cefpiramide Chemical compound C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 PWAUCHMQEXVFJR-PMAPCBKXSA-N 0.000 description 1
- 229960000466 cefpirome Drugs 0.000 description 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229960003844 cefroxadine Drugs 0.000 description 1
- RDMOROXKXONCAL-UEKVPHQBSA-N cefroxadine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)OC)C(O)=O)=CCC=CC1 RDMOROXKXONCAL-UEKVPHQBSA-N 0.000 description 1
- 229960003202 cefsulodin Drugs 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 1
- 229960004366 ceftezole Drugs 0.000 description 1
- DZMVCVMFETWNIU-LDYMZIIASA-N ceftezole Chemical compound O=C([C@@H](NC(=O)CN1N=NN=C1)[C@H]1SC2)N1C(C(=O)O)=C2CSC1=NN=CS1 DZMVCVMFETWNIU-LDYMZIIASA-N 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- NPGNOVNWUSPMDP-UTEPHESZSA-N chembl1650818 Chemical compound N(/[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C(C)(C)C)=C\N1CCCCCC1 NPGNOVNWUSPMDP-UTEPHESZSA-N 0.000 description 1
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960001351 clometocillin Drugs 0.000 description 1
- JKXQBIZCQJLVOS-GSNLGQFWSA-N clometocillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(OC)C1=CC=C(Cl)C(Cl)=C1 JKXQBIZCQJLVOS-GSNLGQFWSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 208000013184 decreased milk production Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960002457 epicillin Drugs 0.000 description 1
- RPBAFSBGYDKNRG-NJBDSQKTSA-N epicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CCC=CC1 RPBAFSBGYDKNRG-NJBDSQKTSA-N 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960003884 hetacillin Drugs 0.000 description 1
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-M loracarbef anion Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)N)=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-M 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003806 metampicillin Drugs 0.000 description 1
- FZECHKJQHUVANE-MCYUEQNJSA-N metampicillin Chemical compound C1([C@@H](N=C)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 FZECHKJQHUVANE-MCYUEQNJSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960000596 penamecillin Drugs 0.000 description 1
- NLOOMWLTUVBWAW-HLLBOEOZSA-N penamecillin Chemical compound N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C)C(=O)CC1=CC=CC=C1 NLOOMWLTUVBWAW-HLLBOEOZSA-N 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NONJJLVGHLVQQM-JHXYUMNGSA-N phenethicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 description 1
- 229960004894 pheneticillin Drugs 0.000 description 1
- BBTOYUUSUQNIIY-ANPZCEIESA-N phenoxymethylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 BBTOYUUSUQNIIY-ANPZCEIESA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 229960003342 pivampicillin Drugs 0.000 description 1
- ZEMIJUDPLILVNQ-ZXFNITATSA-N pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 description 1
- 229960004212 pivmecillinam Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 229940095783 procaine benzylpenicillin Drugs 0.000 description 1
- 229960003672 propicillin Drugs 0.000 description 1
- HOCWPKXKMNXINF-XQERAMJGSA-N propicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(CC)OC1=CC=CC=C1 HOCWPKXKMNXINF-XQERAMJGSA-N 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960004932 sulbenicillin Drugs 0.000 description 1
- OPYGFNJSCUDTBT-PMLPCWDUSA-N sultamicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OCOC(=O)[C@H]2C(S(=O)(=O)[C@H]3N2C(C3)=O)(C)C)(C)C)=CC=CC=C1 OPYGFNJSCUDTBT-PMLPCWDUSA-N 0.000 description 1
- 229960001326 sultamicillin Drugs 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002780 talampicillin Drugs 0.000 description 1
- SOROUYSPFADXSN-SUWVAFIASA-N talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 description 1
- 229960003250 telithromycin Drugs 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9446—Antibacterials
Definitions
- a method for determining bacterial antibiotic resistance or bacterial susceptibility a diagnostic kit for the detection of the antibiotic resistance and use of such diagnostic kit
- the subjects of invention are method for determining bacterial antibiotic resistance or bacterial susceptibility, a diagnostic kit for the detection of the antibiotic resistance and use of such diagnostic kit. Mote precisely a new, fast and efficient method for determining the antibiotic resistance of bacteria, screen test for antibiotic-resistant bacteria and test for the efficiency of the antimicrobial treatment, diagnostic set and use to the measurement of the drug detection or their metabolites are described. A new method for detection of bacterial antibiotic resistance, diagnostic set based on the lateral flow test or lateral immunochromatographic assays to detect drug resistance of the contagious factor and use of detection of the drug and/or products of its/theirs degradations are disclosed.
- Bacterial drug resistance may be detected in different ways. These methods can be divided into techniques used in cell/bacterial culture, e.g. disk diffusion method, colorimetric methods and non-culture techniques among them the most important are genetic techniques, e.g. PCR which enables the detection of DNA/RNA responsible for coding enzyme or based on bio-sensors. Other used methods are techniques based on the immunological techniques, based on the detection of presence special proteins or beta-lactamase enzyme, e.g. immunoblot reaction, slide agglutination test, latex agglutination etc.
- the lateral flow test or lateral immunochromatographic assays are commonly used diagnostic methods used to detect different compounds in body fluids such as serum or urine, or in the supernatant from the tissue culture or different homogenates.
- the existing penicillin detection test e.g. Penicillin Rapid Inspection Test from Nankai biotech company is used to detect the food products penicillin spoilage, but not for the detection of the antibiotic resistance, neither screening tests for antibiotic- resistant bacteria, nor for tests for the efficiency of the antimicrobial treatment. Furthermore they are able to detect only a few antibiotics.
- Patent application No. 2007231923 (pub. 2007-10-04) describes sampling and testing device for the detection of specific molds, allergens, viruses, bacteria, fungi, and other protein containing substances.
- Embodiments of the device include a sampling member slideably engaged with a base that contains a lateral flow strip adapted to detect specific analytes of interest.
- the sampling member defines a solvent reservoir that stores an elution solvent in a fluid-tight manner before the device is used to sample and test environmental surfaces.
- the elution solvent stored in the reservoir is automatically released to a wick assembly of the sampling member.
- the wick assembly includes a wick adapted to receive, distribute, and retain the elution solvent.
- the bacteria detection device is a microarray type of device in which an oligonucleotide, which is based on a nucleotide sequence specific to a genus or species to which a target spore-forming, aerobic bacteria belongs, is immobilized on a substrate. Spore-forming, aerobic bacteria present in a test sample can be easily, rapidly and accurately detected and identified based on the presence or absence of successful hybridization between a probe prepared from the test sample and the oligonucleotide immobilized on the substrate.
- Patent application 2006078951 (publ. 2006-04-13) describes monoclonal antibody binding specifically to the p60 protein of Listeria monocytogenes, a hybridoma cell producing the monoclonal antibody, a test kit comprising the monoclonal antibody, and a method for detecting Listeria monocytogenes using the monoclonal antibody.
- the inventive monoclonal selectively recognizes only Listeria monocytogenes, so that the use of such an antibody allows for rapid determination of the food contamination with these bacteria pathogenic to humans.
- Patent application 2005272113 (publ. 2005-12-08) describes a reagent for the detection of an extracellular enzymatically active protein produced by a beta-hemolytic streptococcus bacteria found in a host biological fluid includes a proteinaceous substrate or a cholesterol-containing membrane substrate for the extracellular protein.
- the substrate is nonspecific within the groups of beta-hemolytic streptococcus bacterium and is in contact with an inert solid matrix.
- Extracellular streptococcus protein found in saliva represents a less invasive source of biological fluid for the determination as to whether a host suffers acute pharyngitis.
- Patent application WO03107007 (publ. 2003-12-24) describes rapid a test method for detecting at least one antigen by means of optical and/or chemical detection, using specific interactions.
- the inventive method is a universal rapid test method, which enables bacteria and viruses to be simultaneously and quantitatively determined.
- Patent description PL 195495 discloses a process for determination of the presence and/or amount of antibiotics containing beta-lactam ring present in a biological fluid and especially in milk.
- the process complexes the antibiotic in the biological fluid with a known amount of recognition agent and then places the mixture of the biological fluid and recognition agent in contact with an antibiotic a support. A determination is made of the amount of the antibiotic present in the biological fluid.
- recognition factor is used BIaR receptor or the BIaR-CTD receptor.
- Patent description No. 6 485 982 describes "including determination of the presence of metabolites of drugs or toxins.
- the assay process and the cell are engineered specifically to detect the presence of a preselected individual ligand present in a body or other fluids.”
- evaluation antibiotic resistance are useful, but expensive and time-consuming. They also require highly qualified staff. According to these disadvantages, there is still a need to develop an antibiotic resistance test and method that could guarantee sensitivity, reliability and should be achieved in a fast, easy, and cheap manner.
- the main aim of this invention is to deliver a method, which could confirm the lack of antibiotic or its presence in concentration, lower than therapeutic concentration, based on the immunoenzymatic detection of medications or the lack of their presence.
- the applicant has just discovered a novel process for detecting antibiotic resistance, screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment by evaluation of presence of antibiotics in a biological fluid, which allows these objectives to be achieved in a noteworthy manner.
- the invention discloses a process of detection of antibiotic resistance or a screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment, which is characterised that antibiotic resistance is detected by the lack of given antibiotic in the body fluids, because the antibiotic resistant bacteria destroy/degrade the antibiotic (to the inactive compounds).
- the presence (or absence) of an antibiotic is detected by the lateral flow test or lateral immunochromatographic assays.
- the subject of invention is a method for determining bacterial antibiotic resistance or bacterial susceptibility, characterised in that, the drug resistance is detected by detection of the given antibiotic in the urine or other body fluids with the diagnostic set based on the lateral flow test or lateral immunochromatographic assays.
- said antibiotic resistance is detected when concentration of a given antibiotic or its active metabolites is lower or equal than therapeutic concentration.
- said antibiotic susceptibility is detected when concentration of a given antibiotic or its active metabolites is higher or equal to therapeutic concentration.
- said method concerns human and/or animal organisms.
- said method could be used as screening method of healthy organisms, which could be asymptomatic carriers of antibiotic resistant bacteria.
- the next subject of invention is a diagnostic kit based on the lateral flow test or lateral immunochromatographic assays for the detection of the antibiotic resistance of the infective factor characterised in that said kit is a diagnostic assay contains a set of antibodies, preferably monoclonal antibodies, for detection of antibiotic resistance by detection of the presence of lack of the given antibiotic wherein said antibiotics are betalactams in biological fluids, especially in urine.
- said set is useful for screening healthy organisms or monitoring treatment efficiency.
- the next subject of invention is an use of a diagnostic kit for detection of drug presence and/or its active metabolites by detection of its concentration in comparison to the therapeutic concentration in the body fluids with the lateral flow test or lateral immunochromatographic assays in screening and treatment of patients during antibiotic therapy to the antibiotic resistance detection in screening of the antibiotic resistance of the given antibiotic.
- antibiotic resistance is stated when concentration of a drug or/and its active metabolites is lower or equal than its therapeutic concentration.
- antibiotic susceptibility is, stated when concentration of a drug or/and its active metabolites are higher or equal to its therapeutic concentration.
- said use concerns human and/or animal organisms.
- it concerns screening of healthy organisms, which could be asymptomatic carriers of antibiotic resistant bacteria.
- Figure 1 illustrates, for better understanding, the test for detection of antibiotic resistance (or screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment), wherein: 1 - input window, 2 - result window, 3 - test window, 4 - printed, 5 - urine or other body fluids, 6 - mobile Ab#l , 7 - bound Ab#2, 8 - bound Ab#3.
- Example Test - diagnostic set - is based on the lateral flow test or lateral immunochromatographic assays for detection of the drug resistance of infective factors, which is characterised, that drug resistance (e.g. antibiotic resistance) of the infective factor/s (e.g. bacteria which cause infection) comprise diagnostic set containing set of antibodies (e.g. monoclonal antibodies) to the antibiotic resistance detection by detection presence or absence of administered drug, and especially beta-lactam antibiotics (list below) in the biological fluids and especially in the urine.
- the above test may be used as a screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment as well.
- patient may be resistant to given beta-lactam antibiotic (e.g. amoxicillin), but it is still administered (with other antibacterial drugs), when the infectious factor is eliminated from the organism the amoxicillin might be detected in the urine again.
- beta-lactam antibiotic e.g. amoxicillin
- antibiotics which can be detected by means of the processes according to the present invention, mention may be made of the following antibiotics: Ampicillin, Pivampicillin, Carbenicillin, Amoxicillin, Carindacillin, Bacampicillin, Epicillin, Pivmecillinam, Azlocillin, Mezlocillin, Mecillinam, Piperacillin, Ticarcillin, Metampicillin, Talampicillin, Sulbenicillin, Temocillin, Hetacillin, Benzylpenicillin, Phenoxymethylpenicillin, Propicillin, Azidocillin, Pheneticillin, Penamecillin, Clometocillin, Benzathine benzylpenicillin, Procaine benzylpenicillin, Benzathine phenoxymethylpenicillin, Dicloxacillin, Cloxacillin, Methicillin, Oxacillin, Flucloxacillin, Sultamicillin, Cefalexin, Cefaloridine, Cefalotin, Cefa
- the lateral flow test (lateral immunochromatographic assays) is a very sensitive method of detection of medication present in urine comparing to HPLC (high performance liquid chromatography). Table 4
- the lateral flow test (lateral immunochromatographic assays) to HPLC (high performance liquid chromatography) for all the beta-lactam antibiotics.
- the lateral flow test (lateral immunochromatographic assays) specificity and sensitivity is 99.99%. Presented is monitoring efficiency of elimination of beta-lactams producing bacteria, when they are absent the penicillins started to be present in urine.
- Bacteria MRSA Metal-resisitant Staphylococcus aureus
- Bacteria MRSA are resistant to all known beta-lactams antibiotics, and in 90% there is a cross-resistance with macrolides and fluorochinolones.
- This can mean resistance to such macrolides as: erythromycin, spiramycin, roxythromycin, clarithromycin, azythromycin, telithromycin, and such fluorochinolones as ofloxacyllin, ciprofloxacillin, pefloxacyllin, norfloxacillin, levofloxacillin, moxyfloxacillin. So the proposed test is also useful in detection (with 90% probability) resistance to these antibiotics.
- Resistance to aminoglicosides is caused by synthesis of the enzyme, which modifies the drug, which is localised on the transposon Tn-4001. So proposed test is also useful to detect resistance to aminoglicosides antibiotics (streptomycin, tobramycin, gentamycin, neomycine, amikacine, netelmycine etc.).
- Proposed diagnostic test may be also very useful in the veterinary and other biological sciences. It may let to discover new mechanisms of drug resistance e.g. presence of endogenic enzymes of drug degradation.
- the lateral flow test (lateral immunochromatographic assays) is cheap, sensitive, efficient, easy to operate device, which (thanks to above mentioned features) may be a useful tool to achieve further progress in medicine, veterinary and other biological sciences.
- the greatest advantage of the proposed lateral flow test is the immediate response for the most important question (from the point of view patient and his/her doctor): is the used treatment effective or not?
- the threshold sensitivity depends on the local epidemiological date and the type of an antibiotic and is compared between 1-999 micrograms/ml. Below this border (1-999 micrograms/ml) the result is recognised as negative, i.e. the antibiotic level is below this antibiotic concentration it means that the bacteria (responsible for infection or co- infection) are resistant to administered antibiotic.
- the positive result i.e. detection of antibiotic in urine
- penicillinase or similar enzyme which degrade the antibiotic
- Test consists of a box with three windows: the first one - administration of a urine (or other body fluids), the second one - a result window, and the third one - a control window.
- a wick from a material (e.g. paper) which is easy to moisten by the biological fluids.
- On the "wick” there are: a) mobile primary antibody Ab#l (e.g. monoclonal antibody) - recognition agent against given antibiotic (or its active metabolite); b) secondary antibody Ab#2 (e.g. monoclonal antibody) which connects to the other epitop of the given antibiotic.
- the secondary antibody is coupled with to a labelling agent. This labelling agent can be of diverse nature.
- the labelling agent can be of particular type such as metallic colloidal particles (platinum, gold, silver, etc.), colloidal particles of selenium, carbon, sulphur or tellurium, or alternatively colloidal particles of coloured synthetic latexes.
- the labelling agent can also be a fluorescent substance, the labelling agent can also be enzymatic
- the fluid fraction along with its dissolved components including given antibiotic moves along with the liquid front.
- control window shows plus to indicate that the antibodies in the paper (or the other spongy substance) were alright and working. This is to ensure the patient that the device had not become overheated (or damaged in any other way) during transit. If it had, patient would have two minuses - the second one telling the patient to take the device back because it could be a false negative.
- the urine (or other body fluid) is applied.
- the test result is "minus-plus.” It is also possible to detect antibiotic resistance by analysis of patient's body fluids. When antibiotic's concentration is higher or equals to the minimal inhibitory concentration in the body fluids, the bacteria is susceptible to the given antibiotic. In case when antibiotic's concentration is lower than the minimal inhibitory concentration in the body fluids the infectious factor is resistant to the given antibiotic. It could be done by redox reaction with iron chloride.
- the beta-lactam antibiotics are detected by hydrolysis of present antibiotic in the urine to the hydroxam acids (e.g. hydroxylamin) and FeCl 3 is added. In case of presence of beta-lactams (lack of antibiotic resistance) the violet colour appears.
- the antibiotic presence detection of antibiotic resistance or susceptibility
- the process according to the invention allow the detection of antibiotics resistance in biological fluids such as urine, saliva, milk, blood, serum saliva, culture media, pus, wound discharge etc.
- biological fluids such as urine, saliva, milk, blood, serum saliva, culture media, pus, wound discharge etc.
- Amoxicillin is a beta-lactam antibiotic, which is active against Gram-positive and Gram-negative organisms but is inactivated by penicillinases, including those produced by Staphylococcus aureus and by common Gram-negative bacilli such as Escherichia coli. Amoxicillin is recommended as "first - line" antibiotic in most infections.
- microbiological result was known - Staphylococcus epidermidis, amoxicillin susceptible, the microbiological culture result confirmed the lateral flow test.
- Phenoxymethylpenicillin is an oral beta-lactam antibiotic. Its antibacterial spectrum compares Streptococcus spp. and Staphylococcus spp. (which do not produce penicillinases). Phenoxymethylpenicillin (Penicillin V) is recommended as "first - line" antibiotic in most throat infections. Two patients, A and B complained of a usual bacterial throat infection. They were admitted by their General Practitioner who prescribed them a standardise of 500 mg four times a day. The General Practitioner recommended also an antibiotic resistance lateral flow test to be done 6 hours after first dose of an antibiotic. He took also a standard bacteriological swab.
- Patient A did a test and the result was positive (it showed that antibiotic is in the urine in concentration higher than therapeutic ones) so the treatment was continued.
- Patient B did a test as well and the result was negative (it showed that antibiotic is in the urine in concentration lower than therapeutic or was absent).
- the treatment was changed into amoxicillin with clavulanic acid (in standard doses). Six hours after administration of the antibiotics another test was carried out, which showed susceptibility on the given treatment.
- Cefalexin is a "first generation" of cefalosporins - broad-spectrum antibiotics that are used in the treatment septicaemia, pneumonia, meningitis, urinary tract infections etc.
- the pharmacology of the cefalosporins is similar to that of the penicillins, excretion being principal renal.
- Pregnant patient (30-gestation week) complains of symptoms of lower urinary tract bacterial infection.
- Cefuroxime is a "second generation " cephalosporin that is less susceptible than the earlier cephalosporins to inactivation by beta-lactamases (except extended spectrum beta-lactamases). It is, therefore, active against certain bacteria, which are resistant to the other drugs, and has greater activity against certain bacteria.
- Sepsis is a serious medical condition characterised by a whole-body inflammatory state caused by infection. Sepsis is broadly defined as the presence of various pus-forming and other pathogenic organisms, or their toxins, in the blood or tissues. Sepsis is common and also more dangerous in elderly, immunocompromised, and critically ill patients.
- ICU intensive care unit
- a common antibiotic regimen in infants with suspected sepsis is a beta-lactam antibiotic (usually ampicillin) in combination with an aminoglycoside (usually gentamicin) or a third-generation cephalosporin (usually cefotaxime — ceftriaxone is generally avoided in neonates due to the theoretical risk of causing biliary stasis.)
- the organisms which are targeted are species that predominate in the female genitourinary tract and to which neonates are especially vulnerable to, specifically Group B Streptococcus, Escherichia coli, and Listeria monocytogenes (This is the main rationale for using ampicillin versus other beta-lactams.)
- neonates are also vulnerable to other common pathogens that can cause meningitis and bacteremia such as Streptococcus pneumoniae and Neisseria meningitidis.
- anaerobic species are suspected (such as in cases where necrot)
- the identification of the causative pathogen in sepsis can provide useful information to the doctor. In the past, this has been accomplished by growing bacterial cultures. However, this is a slow process as it takes a few days to grow up the cultures and correctly identify the pathogens.
- New molecular diagnostic tests e.g. Roche's SeptiFast and SIRS Labs' Vyoo
- Roche's SeptiFast and SIRS Labs' Vyoo are now available that uses genetic material from the pathogen to quickly (within hours) provide results.
- current practice has been to skip these tests altogether and directly prescribe broad-spectrum antibiotics to the patient.
- the proposed test has a greater advantage over so far proposed tests. An 8 year old child was admitted to hospital with sepsis. The sample of blood was taken for bacteriological test (culture and antibiotic resistance).
- the hospital does not have a molecular laboratory.
- the standard antibiotic treatment with IV cefuroxime was introduced. After 70 min since antibiotic administration it was possible to obtain the first urine sample (in case of emergency when urine is not accessible it is possible to use blood serum or even saliva). The result was "probably positive", and because of the direct life threatening the test was repeated after 3 and 6 hrs of the first administration of an antibiotic, to confirm the result and monitor the efficiency of treatment as well.
- the above case is an example that results obtained in proposed tests are faster than all tests used so far, is simpler and cheaper.
- the above test enables to detect antibiotic resistance even in case of an unknown mechanism.
- Treatment monitoring/supervision A very important feature of the proposed antibiotic resistance diagnostic set based on the lateral flow test or lateral immunochromatographic assays is using it as a test for the efficiency of antibacterial treatment. It can be described by below example.
- Screening examination is aimed to detect asymptomatic carries of potentially pathogenic microorganisms, which produce penicillinase.
- the screening is extremely important in case of persons who are exposed on occupational injuries (e.g. firemen) - in case of broken bones the wound could be settled by pathogenic microorganisms, which could be very difficult to eradicate.
- the screening has an importance for patients who have artificial implants (e.g. artificial heart valves, etc.) because there is a risk of serious complications in case of colonisation by pathogenic organisms.
- the screening is very useful for patients who have to take the antibiotics as prevention against infection (e.g. in case of cystic fibrosis, after splenectomy, after tick bit - to prevent Lyme disease etc.), in such case early detection of beta-lactamase producing bacteria helps to change ineffective antibiotic prevention.
- test test patient takes a standard dose of 250 mg of amoxicillin and after 6 hrs a few drops of urine is put on the lateral flow test (or lateral immunochromatographic assays). In case of positive results (when the antibiotic is detected in urine) there is a proof of proper treatment, in case of negative result (when antibiotic is not detectable) the further examination should be done to find a source of potential infection.
- lateral flow test or lateral immunochromatographic assays
- Mastitis is the inflammation of the mammary gland. Mastitis is the most common and the most expensive disease of the cows. This disease and resulting infection can significantly reduce the amount and quality milk production. Mastitis is most commonly found in dairy herds. It is now recognised as a growing problem in beef herds, too. This is a growing problem in beef herds, and can result in weaning weights being reduced by 7% to 12.5%. The cost of one case of mastitis is about 370 €. Different types of mastitis could concern from 30-80 % of the herd. Two types of mastitis (infectious and non-infectious) can occur. The vast majority (99%) of the cases is infectious.
- streptococci ⁇ Streptococcus agalactiae, Streptococcus dysgalactiae i Streptococcus uteris), staphylococci (e.g. Staphylococcus aureus and others,), and E. coli.
- Antibiotics are the main group of medications which are use in the treatment and prevention of mastitis. The efficiency of treatment is constanty decreasing (even new antibiotic generations are enter into treatment). The most important reason is that bacteria acquire resistance to widely used antibiotics.
- the veterinary guidelines recommend the bacterial culture with susceptibility (disk diffusion method) before treatment. Otherwise the treatment could be ineffective and a farmer would lose money because of long treatment and decreased milk production.
- Diagnosed mastitis was commenced with standard cloxacillin suspension, which was administered to an udder (500mg/10g). The drug was administered after udders' were disinfected with careful milking of the infected udder. During the next milking the milk sample was taken, the presence of antibiotic was detected what means the infectious factor is susceptible on administered antibiotic, and the therapy may be continued during the next three days in 24hrs intervals (to prevent recurrence of the disease). In case of negative result the antibiotic would have to be changed. The usage of the new lateral flow test or lateral immunochromatographic assays to detect antibiotic resistance let to decreasing the cost, the given result is faster and lead to the short the pain of the animal.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The subjects of invention are method for determining bacterial antibiotic resistance or bacterial susceptibility, a diagnostic kit for the detection of the antibiotic resistance and use of such diagnostic kit. Mote precisely a new, fast and efficient method for determining the antibiotic resistance of bacteria, screen test for antibiotic-resistant bacteria and test for the efficiency of the antimicrobial treatment, diagnostic set and use to the measurement of the drug detection or their metabolites are described. A new method for detection of bacterial antibiotic resistance, diagnostic set based on the lateral flow test or lateral immunochromatographic assays to detect drug resistance of the contagious factor and use of detection of the drug and/or products of its/theirs degradations are disclosed.
Description
A method for determining bacterial antibiotic resistance or bacterial susceptibility, a diagnostic kit for the detection of the antibiotic resistance and use of such diagnostic kit
The subjects of invention are method for determining bacterial antibiotic resistance or bacterial susceptibility, a diagnostic kit for the detection of the antibiotic resistance and use of such diagnostic kit. Mote precisely a new, fast and efficient method for determining the antibiotic resistance of bacteria, screen test for antibiotic-resistant bacteria and test for the efficiency of the antimicrobial treatment, diagnostic set and use to the measurement of the drug detection or their metabolites are described. A new method for detection of bacterial antibiotic resistance, diagnostic set based on the lateral flow test or lateral immunochromatographic assays to detect drug resistance of the contagious factor and use of detection of the drug and/or products of its/theirs degradations are disclosed.
Bacterial drug resistance may be detected in different ways. These methods can be divided into techniques used in cell/bacterial culture, e.g. disk diffusion method, colorimetric methods and non-culture techniques among them the most important are genetic techniques, e.g. PCR which enables the detection of DNA/RNA responsible for coding enzyme or based on bio-sensors. Other used methods are techniques based on the immunological techniques, based on the detection of presence special proteins or beta-lactamase enzyme, e.g. immunoblot reaction, slide agglutination test, latex agglutination etc. The lateral flow test or lateral immunochromatographic assays are commonly used diagnostic methods used to detect different compounds in body fluids such as serum or urine, or in the supernatant from the tissue culture or different homogenates.
The existing penicillin detection test, e.g. Penicillin Rapid Inspection Test from Nankai biotech company is used to detect the food products penicillin spoilage, but not for the detection of the antibiotic resistance, neither screening tests for antibiotic- resistant bacteria, nor for tests for the efficiency of the antimicrobial treatment. Furthermore they are able to detect only a few antibiotics.
Authors of the article "Detection of Antimicrobial Activity in Urine for Epidemiologic Studies of Antibiotic Use" Yung-Ching Liu, Wen-Kuei Huang, Tsai-Shu Huang and Calvin M. Kunin published in the J Formos Med Assoc 1996 Jun;95(6):464- 8, described that presence of antibacterial agents in the urine may cause an unreliable results of bacterial culture in the urine. The authors propose a new test to evaluate these unreliable results by developing bacterial culture Bacillus stearothermophilus.
Wu JJ et al. described that in view of the high rate of occurrence of antimicrobial agents in urine specimens and the lack of information provided by most physicians to laboratories, a screening method (the culture of Bacillus stearothermophilus with urine sample as the indicator method) to detect the presence (or absence) of antimicrobials in urine specimens may be a useful tool [Wu JJ, Chien ML, Lee N, Chou SF, Wang HM, Tsai WC, Microbiologic assay for detection of antimicrobial agents in urine, J. Formos Med Assoc. 1996 Jun;95(6):464-8].
Patent application No. 2007231923 (pub. 2007-10-04) describes sampling and testing device for the detection of specific molds, allergens, viruses, bacteria, fungi, and other protein containing substances. Embodiments of the device include a sampling member slideably engaged with a base that contains a lateral flow strip adapted to detect specific analytes of interest. The sampling member defines a solvent reservoir that stores an elution solvent in a fluid-tight manner before the device is used to sample and test environmental surfaces. During slideable withdrawal of the sampling member from the base, the elution solvent stored in the reservoir is automatically released to a wick assembly of the sampling member. The wick assembly includes a wick adapted to receive, distribute, and retain the elution solvent. After a user samples an environmental surface for an analyte of interest with the elution solvent wetted wick, the sampling member is returned to the base where the wick contacts the lateral flow strip contained in the base. The wick transfers at least a portion of analyte and the elution solvent to the lateral flow strip for the calorimetric detection of specific allergens, viruses, bacteria, and other protein containing substances in the sample. The colorimetric results of the test are displayed through a window in the base.
Another patent application US2007212715 (publ. 2007-09-13) describes a bacteria detection device, bacteria detection method and bacteria detection kit enabling rapid and accurate determination of bacteria present in a test sample, and particularly spore-forming, aerobic bacteria, with a simple procedure. The bacteria detection device according to the present invention is a microarray type of device in which an oligonucleotide, which is based on a nucleotide sequence specific to a genus or species to which a target spore-forming, aerobic bacteria belongs, is immobilized on a substrate. Spore-forming, aerobic bacteria present in a test sample can be easily, rapidly and accurately detected and identified based on the presence or absence of successful hybridization between a probe prepared from the test sample and the oligonucleotide immobilized on the substrate.
Patent application 2006078951 (publ. 2006-04-13) describes monoclonal antibody binding specifically to the p60 protein of Listeria monocytogenes, a hybridoma cell producing the monoclonal antibody, a test kit comprising the monoclonal antibody, and a method for detecting Listeria monocytogenes using the monoclonal antibody. The inventive monoclonal selectively recognizes only Listeria monocytogenes, so that the use of such an antibody allows for rapid determination of the food contamination with these bacteria pathogenic to humans.
Patent application 2005272113 (publ. 2005-12-08) describes a reagent for the detection of an extracellular enzymatically active protein produced by a beta-hemolytic streptococcus bacteria found in a host biological fluid includes a proteinaceous substrate or a cholesterol-containing membrane substrate for the extracellular protein. The substrate is nonspecific within the groups of beta-hemolytic streptococcus bacterium and is in contact with an inert solid matrix. Upon reaction between the streptococcus enzymatically activate protein and the substrate, a color change discernable by an unaided human eye results. Extracellular streptococcus protein found in saliva represents a less invasive source of biological fluid for the determination as to whether a host suffers acute pharyngitis.
Patent application WO03107007 (publ. 2003-12-24) describes rapid a test method for detecting at least one antigen by means of optical and/or chemical detection, using specific interactions. The inventive method is a universal rapid test method, which enables bacteria and viruses to be simultaneously and quantitatively determined.
Patent description PL 195495 (publ. 1999-12-29) discloses a process for determination of the presence and/or amount of antibiotics containing beta-lactam ring
present in a biological fluid and especially in milk. The process complexes the antibiotic in the biological fluid with a known amount of recognition agent and then places the mixture of the biological fluid and recognition agent in contact with an antibiotic a support. A determination is made of the amount of the antibiotic present in the biological fluid. As recognition factor is used BIaR receptor or the BIaR-CTD receptor.
Patent description No. 6 485 982 describes "including determination of the presence of metabolites of drugs or toxins. The assay process and the cell are engineered specifically to detect the presence of a preselected individual ligand present in a body or other fluids." Apart from the described above techniques which are used in medical (or veterinary) diagnostics, disks diffusion methods and genetic detection of different antibiotic resistance plasmids, evaluation antibiotic resistance are useful, but expensive and time-consuming. They also require highly qualified staff. According to these disadvantages, there is still a need to develop an antibiotic resistance test and method that could guarantee sensitivity, reliability and should be achieved in a fast, easy, and cheap manner.
The main aim of this invention is to deliver a method, which could confirm the lack of antibiotic or its presence in concentration, lower than therapeutic concentration, based on the immunoenzymatic detection of medications or the lack of their presence. The applicant has just discovered a novel process for detecting antibiotic resistance, screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment by evaluation of presence of antibiotics in a biological fluid, which allows these objectives to be achieved in a noteworthy manner.
The invention discloses a process of detection of antibiotic resistance or a screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment, which is characterised that antibiotic resistance is detected by the lack of given antibiotic in the body fluids, because the antibiotic resistant bacteria destroy/degrade the antibiotic (to the inactive compounds). The presence (or absence) of an antibiotic is detected by the lateral flow test or lateral immunochromatographic assays.
The subject of invention is a method for determining bacterial antibiotic resistance or bacterial susceptibility, characterised in that, the drug resistance is detected by
detection of the given antibiotic in the urine or other body fluids with the diagnostic set based on the lateral flow test or lateral immunochromatographic assays.
Preferably, said antibiotic resistance is detected when concentration of a given antibiotic or its active metabolites is lower or equal than therapeutic concentration. Preferably, said antibiotic susceptibility is detected when concentration of a given antibiotic or its active metabolites is higher or equal to therapeutic concentration.
Preferably, said method concerns human and/or animal organisms.
Preferably, said method could be used as screening method of healthy organisms, which could be asymptomatic carriers of antibiotic resistant bacteria. The next subject of invention is a diagnostic kit based on the lateral flow test or lateral immunochromatographic assays for the detection of the antibiotic resistance of the infective factor characterised in that said kit is a diagnostic assay contains a set of antibodies, preferably monoclonal antibodies, for detection of antibiotic resistance by detection of the presence of lack of the given antibiotic wherein said antibiotics are betalactams in biological fluids, especially in urine.
Preferably, said set is useful for screening healthy organisms or monitoring treatment efficiency.
The next subject of invention is an use of a diagnostic kit for detection of drug presence and/or its active metabolites by detection of its concentration in comparison to the therapeutic concentration in the body fluids with the lateral flow test or lateral immunochromatographic assays in screening and treatment of patients during antibiotic therapy to the antibiotic resistance detection in screening of the antibiotic resistance of the given antibiotic.
Preferably, antibiotic resistance is stated when concentration of a drug or/and its active metabolites is lower or equal than its therapeutic concentration.
Preferably, antibiotic susceptibility is, stated when concentration of a drug or/and its active metabolites are higher or equal to its therapeutic concentration.
Preferably, said use concerns human and/or animal organisms.
Preferably, it concerns screening of healthy organisms, which could be asymptomatic carriers of antibiotic resistant bacteria.
Figure 1 illustrates, for better understanding, the test for detection of antibiotic resistance (or screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment), wherein:
1 - input window, 2 - result window, 3 - test window, 4 - printed, 5 - urine or other body fluids, 6 - mobile Ab#l , 7 - bound Ab#2, 8 - bound Ab#3.
Below are some examples of the usage of the above defined invention.
Example Test - diagnostic set - is based on the lateral flow test or lateral immunochromatographic assays for detection of the drug resistance of infective factors, which is characterised, that drug resistance (e.g. antibiotic resistance) of the infective factor/s (e.g. bacteria which cause infection) comprise diagnostic set containing set of antibodies (e.g. monoclonal antibodies) to the antibiotic resistance detection by detection presence or absence of administered drug, and especially beta-lactam antibiotics (list below) in the biological fluids and especially in the urine. The above test may be used as a screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment as well. As an example: patient may be resistant to given beta-lactam antibiotic (e.g. amoxicillin), but it is still administered (with other antibacterial drugs), when the infectious factor is eliminated from the organism the amoxicillin might be detected in the urine again.
As examples of antibiotics which can be detected by means of the processes according to the present invention, mention may be made of the following antibiotics: Ampicillin, Pivampicillin, Carbenicillin, Amoxicillin, Carindacillin, Bacampicillin, Epicillin, Pivmecillinam, Azlocillin, Mezlocillin, Mecillinam, Piperacillin, Ticarcillin, Metampicillin, Talampicillin, Sulbenicillin, Temocillin, Hetacillin, Benzylpenicillin, Phenoxymethylpenicillin, Propicillin, Azidocillin, Pheneticillin, Penamecillin, Clometocillin, Benzathine benzylpenicillin, Procaine benzylpenicillin, Benzathine phenoxymethylpenicillin, Dicloxacillin, Cloxacillin, Methicillin, Oxacillin, Flucloxacillin, Sultamicillin, Cefalexin, Cefaloridine, Cefalotin, Cefazolin, Cefadroxil, Cefazedone, Cefatrizine, Cefapirin, Cefradine, Cefacetrile, Cefroxadine, Ceftezole, Cefoxitin, Cefuroxime, Cefamandole, Cefaclor, Cefotetan, Cefonicide, Cefotiam, Loracarbef, Cefmetazole, Cefprozil, Ceforanide, Cefotaxime, Ceftazidime, Cefsulodin, Ceftriaxone, Cefmenoxime, Latamoxef, Ceftizoxime, Cefixime, Cefodizime, Cefetamet, Cefpiramide, Cefoperazone, Cefpodoxime, Ceftibuten, Cefdinir, Cefditoren, Ceftriaxone, Cefoperazone, Cefepime, Cefpirome, Aztreonam, Meropenems, Ertapenem, Imipenem.
The processes according to the invention allow the detection of antibiotics containing beta-lactam ring (or other antibiotics) in biological fluids such as urine, milk, blood, serum, saliva, pus and other wound discharges, or culture media (e.g. supernatant).
Below presented results confirms that the lateral flow test or lateral immunochromatographic assays is a useful alternative for so far used test like disk diffusion methods (and others), ESR or CRP.
Table 1
Comparison of the antibiotic resistance with the disk diffusion method to the lateral flow test (lateral immunochromatographic assays). The results of the lateral flow test are more correlated with patients' clinical condition.
The results about antibiotic resistance are obtained much more faster with lateral flow test (lateral immunochromatographic assays) than standard methods what is vitally important in case of serious infections (e.g. sepsis) or in case of patients with decreased immunological barrier (e.g. small children, elderly peoples, in case of AIDS, neoplastic diseases etc.)
Table 2
Comparison of the time required to detect the antibiotic resistance with the disk diffusion method to the lateral flow test (lateral immunochromatographic assays).
As mentioned above the great advantage of the lateral flow test is the fast result obtained. It depends on the way of administration of the drug.
Table 3
Comparison of the time required to detect the antibiotic resistance with the lateral flow test (lateral immunochromatographic assays) in dependence of the way of administration of the drug.
The lateral flow test (lateral immunochromatographic assays) is a very sensitive method of detection of medication present in urine comparing to HPLC (high performance liquid chromatography).
Table 4
Comparison of the lateral flow test (lateral immunochromatographic assays) to HPLC (high performance liquid chromatography) for all the beta-lactam antibiotics. The lateral flow test (lateral immunochromatographic assays) specificity and sensitivity is 99.99%. Presented is monitoring efficiency of elimination of beta-lactams producing bacteria, when they are absent the penicillins started to be present in urine.
Bacteria MRSA (Methicillin-resisitant Staphylococcus aureus) are resistant to all known beta-lactams antibiotics, and in 90% there is a cross-resistance with macrolides and fluorochinolones. This can mean resistance to such macrolides as: erythromycin, spiramycin, roxythromycin, clarithromycin, azythromycin, telithromycin, and such fluorochinolones as ofloxacyllin, ciprofloxacillin, pefloxacyllin, norfloxacillin, levofloxacillin, moxyfloxacillin. So the proposed test is also useful in detection (with 90% probability) resistance to these antibiotics.
Resistance to aminoglicosides is caused by synthesis of the enzyme, which modifies the drug, which is localised on the transposon Tn-4001. So proposed test is also useful to detect resistance to aminoglicosides antibiotics (streptomycin, tobramycin, gentamycin, neomycine, amikacine, netelmycine etc.).
Proposed diagnostic test may be also very useful in the veterinary and other biological sciences. It may let to discover new mechanisms of drug resistance e.g. presence of endogenic enzymes of drug degradation. The lateral flow test (lateral immunochromatographic assays) is cheap, sensitive, efficient, easy to operate device, which (thanks to above mentioned features) may be a useful tool to achieve further progress in medicine, veterinary and other biological sciences.
The greatest advantage of the proposed lateral flow test (lateral immunochromatographic assays) is the immediate response for the most important question (from the point of view patient and his/her doctor): is the used treatment effective or not?
The threshold sensitivity depends on the local epidemiological date and the type of an antibiotic and is compared between 1-999 micrograms/ml. Below this border (1-999 micrograms/ml) the result is recognised as negative, i.e. the antibiotic level is below this antibiotic concentration it means that the bacteria (responsible for infection or co- infection) are resistant to administered antibiotic.
Test's sensitivity and specificity
In case of negative test result, i.e. lack of antibiotic in urine - or other body fluids, correlation with the patient's clinical condition is above 99%.
But the positive result (i.e. detection of antibiotic in urine) means that the penicillinase (or similar enzyme which degrade the antibiotic) is not produced, but do not exclude antibiotic resistance on the other way, such as:
- decreased affinity for penicillin- binding proteins (e.g. for cefuroxime);
- impermeability or lack of cell wall;
- mechanism of efflux pumps. Above mechanisms are very rare and do not decrease the usefulness of proposed test.
Test description (fig. 1)
Test consists of a box with three windows: the first one - administration of a urine (or other body fluids), the second one - a result window, and the third one - a control window. Inside the container, there is a wick from a material (e.g. paper) which is easy to moisten by the biological fluids. On the "wick" there are: a) mobile primary antibody Ab#l (e.g. monoclonal antibody) - recognition agent against given antibiotic (or its active metabolite); b) secondary antibody Ab#2 (e.g. monoclonal antibody) which connects to the other epitop of the given antibiotic. The secondary antibody is coupled with to a labelling agent. This labelling agent can be of diverse nature. The labelling agent can be of particular type such as metallic colloidal particles (platinum, gold, silver, etc.), colloidal particles of selenium, carbon, sulphur or tellurium, or alternatively colloidal particles of coloured synthetic latexes. The labelling agent can also be a fluorescent substance, the labelling agent can also be enzymatic
(e.g. a peroxidase, a phosphatase etc.) with any other substrate which could produce coloured products; c) another antibody Ab#3 (e.g. monoclonal antibody) against antibody 1 anti-Ab#l
There are printed two minuses on the wick.
General description of the test:
Positive result (when patient's infectious factor does not produce beta-lactamases or other enzymes which inactivate given antibiotic): L A few drops of urine (or other body fluid) are placed in the application window.
2. The fluid fraction along with its dissolved components including given antibiotic moves along with the liquid front.
3. When the fluid reaches the unbound Ab#l, which is in great excess, the given antibiotic begins reacting with Ab#l, but the complexes and the excess unreacted Ab#l flow along with the current.
4. When this reaches the line where Ab#2 is immobilised to the paper, another portion of the given antibiotic is "displayed" by Ab#l and binds with Ab#2. When this happens, the distorted Ab#2 triggers an enzyme (or other substance) to start making an insoluble dye, which upon accumulating causes the vertical bar on the "plus sign" to become visible.
5. The fluid front continues moving along and eventually crosses the "control window," where the excess Ab#l starts reacting with Ab#3 (also known as: anti- Ab#l), and that triggers the formation of a dye that completes the vertical portion of that plus sign. The control window shows plus to indicate that the antibodies in the paper (or the other spongy substance) were alright and working. This is to ensure the patient that the device had not become overheated (or damaged in any other way) during transit. If it had, patient would have two minuses - the second one telling the patient to take the device back because it could be a false negative.
6. Thus patient who received a proper antibiotic treatment ends up with two pluses.
Negative result (when patient's infectious factor produces beta-lactamases or other enzymes which inactivate given antibiotic):
1. The urine (or other body fluid) is applied.
2. When the fluid meets Ab#l, there is no given antibiotic to react with it. Only Ab#l floats along with the current. 3. In the "result" window, there is no "displayed" antibiotic to react with Ab#2, and no colour reaction occurs. Only the printed minus continues to be shown.
4. Finally, in the control window, the Ab#l is bound to Ab#3 and the "plus" is revealed, showing that the antibodies were effective, and that the fluid had flowed that far - far enough.
5. The test result is "minus-plus." It is also possible to detect antibiotic resistance by analysis of patient's body fluids. When antibiotic's concentration is higher or equals to the minimal inhibitory concentration in the body fluids, the bacteria is susceptible to the given antibiotic. In case when antibiotic's concentration is lower than the minimal inhibitory concentration in the body fluids the infectious factor is resistant to the given antibiotic. It could be done by redox reaction with iron chloride. The beta-lactam antibiotics are detected by hydrolysis of present antibiotic in the urine to the hydroxam acids (e.g. hydroxylamin) and FeCl3 is added. In case of presence of beta-lactams (lack of antibiotic resistance) the violet colour appears. The antibiotic presence (detection of antibiotic resistance or susceptibility) may be detected (by evaluation of the antibiotic concentration) also with the usage of such devices as HPLC, gas chromatography and many other analytical devices which enables such analysis.
The process according to the invention allow the detection of antibiotics resistance in biological fluids such as urine, saliva, milk, blood, serum saliva, culture media, pus, wound discharge etc. The examples which follow illustrate various aspects and methods for implementing the present invention, without, however limiting its scope.
Example 1
Antibiotic resistance detection of in case of amoxicillin treatment
Amoxicillin is a beta-lactam antibiotic, which is active against Gram-positive and Gram-negative organisms but is inactivated by penicillinases, including those produced by Staphylococcus aureus and by common Gram-negative bacilli such as Escherichia coli. Amoxicillin is recommended as "first - line" antibiotic in most infections.
A patient, four days after natural delivery and breast-feeding, was complaining of infection of unknown origin with high temperature (39°C) etc. Doctor prescribed amoxicillin Ig twice daily and recommended proposed test (as a control the microbiological swab from lochia was taken). Patient took a urine sample and did test about 6 hours after first dose of the antibiotic.
Six hours after first dose of the antibiotic, the test's result was positive (an antibiotic was present in the urine), the therapy was continued.
After three days (when patient felt much better) the microbiological result was known - Staphylococcus epidermidis, amoxicillin susceptible, the microbiological culture result confirmed the lateral flow test.
Example 2
Antibiotic resistance detection of in case of phenoxymethylpenicillin (Penicillin V) treatment
Given example antibiotic resistant detection during usual phenoxymethylpenicillin (Penicillin V) treatment in case of bacterial infection of the throat.
Phenoxymethylpenicillin (Penicillin V) is an oral beta-lactam antibiotic. Its antibacterial spectrum compares Streptococcus spp. and Staphylococcus spp. (which do not produce penicillinases). Phenoxymethylpenicillin (Penicillin V) is recommended as "first - line" antibiotic in most throat infections. Two patients, A and B complained of a usual bacterial throat infection. They were admitted by their General Practitioner who prescribed them a standardise of 500 mg four times a day. The General Practitioner recommended also an antibiotic resistance lateral flow test to be done 6 hours after first dose of an antibiotic. He took also a standard bacteriological swab. Patient A did a test and the result was positive (it showed that antibiotic is in the urine in concentration higher than therapeutic ones) so the treatment was continued. Patient B did a test as well and the result was negative (it showed that antibiotic is in the urine in concentration lower than therapeutic or was absent). The treatment was changed into amoxicillin with clavulanic acid (in standard doses). Six hours after administration of the antibiotics another test was carried out, which showed susceptibility on the given treatment.
Four days later both patients were checked by their doctor who found improvement in their health status. The doctor recommended continuation of the treatment. The results of the bacterial culture and antibiotic resistance (disk diffusion method) confirmed the fitness for purpose. Patient A was infected with Streptococcus pyogenes phenoxymethylpenicillin - susceptible and patient B was infected with Streptococcus pyogenes as well, phenoxymethylpenicillin -resistant. After several days both patient
recovered, but in case of patient B the antibiotic resistance lateral flow test helped to find the proper antibiotic, and save the time to find the proper treatment.
Example 3
Antibiotic resistance detection of in case of cefalexin treatment Given example antibiotic resistant detection during usual cefalexin treatment in case of lower urinary tract bacterial infection. Cefalexin is a "first generation" of cefalosporins - broad-spectrum antibiotics that are used in the treatment septicaemia, pneumonia, meningitis, urinary tract infections etc. The pharmacology of the cefalosporins is similar to that of the penicillins, excretion being principal renal. Pregnant patient (30-gestation week) complains of symptoms of lower urinary tract bacterial infection. After examination doctor prescribed cefalexin 250 mg four times a day, bacterial culture (with antibiotic resistance) from a urine sample and (in addition) antibiotic resistance lateral flow test 6 hours after the first dose of the antibiotic. The patient was informed that in case of a negative result (when the antibiotic would not be present in urine) she had to contact her doctor again to have her antibiotic changed. Inappropriate treatment of urinary tract infections may lead to the pregnancy complications.
The result was positive, patient continued therapy, during the next visit the result of bacterial culture and disk diffusion method confirmed the result of antibiotic resistance lateral flow test, S. saprophytics cefalexin susceptible was the infectious factor.
Example 4
Antibiotic resistance detection of in case of cefuroxime treatment
Given example antibiotic resistant detection during cefuroxime treatment in case of septicaemia. Cefuroxime is a "second generation " cephalosporin that is less susceptible than the earlier cephalosporins to inactivation by beta-lactamases (except extended spectrum beta-lactamases). It is, therefore, active against certain bacteria, which are resistant to the other drugs, and has greater activity against certain bacteria. Sepsis is a serious medical condition characterised by a whole-body inflammatory state caused by infection. Sepsis is broadly defined as the presence of various pus-forming and other pathogenic organisms, or their toxins, in the blood or tissues. Sepsis is common and also more dangerous in elderly, immunocompromised, and critically ill patients. It occurs in l%-2% of all hospitalisations and accounts for as much as 25% of
intensive care unit (ICU) bed utilization. It is a major cause of death in intensive care units world-wide, with mortality rates that range from 20% for sepsis to 40% for severe sepsis to >60% for septic shock. The therapy of sepsis rests on antibiotics and support of basic life functions. A problem in the adequate management of septic patients has been the delay in administering therapy after sepsis has been recognised. Published studies have demonstrated that for every hour delay in the administration of appropriate antibiotic therapy there is an associated 7% rise in mortality.
It is worth to mention that in neonates, sepsis is difficult to diagnose clinically. They may be relatively asymptomatic until hemodynamic and respiratory collapse is imminent, so if there is even a remote suspicion of sepsis, they are frequently treated with antibiotics empirically until cultures are sufficiently proven to be negative. In addition to fluid resuscitation and supportive care, a common antibiotic regimen in infants with suspected sepsis is a beta-lactam antibiotic (usually ampicillin) in combination with an aminoglycoside (usually gentamicin) or a third-generation cephalosporin (usually cefotaxime — ceftriaxone is generally avoided in neonates due to the theoretical risk of causing biliary stasis.) The organisms which are targeted are species that predominate in the female genitourinary tract and to which neonates are especially vulnerable to, specifically Group B Streptococcus, Escherichia coli, and Listeria monocytogenes (This is the main rationale for using ampicillin versus other beta-lactams.) Of course, neonates are also vulnerable to other common pathogens that can cause meningitis and bacteremia such as Streptococcus pneumoniae and Neisseria meningitidis. Although uncommon, if anaerobic species are suspected (such as in cases where necrotizing enterocolitis or intestinal perforation is a concern), clindamycin is often added. Diagnosis
The identification of the causative pathogen in sepsis can provide useful information to the doctor. In the past, this has been accomplished by growing bacterial cultures. However, this is a slow process as it takes a few days to grow up the cultures and correctly identify the pathogens. New molecular diagnostic tests (e.g. Roche's SeptiFast and SIRS Labs' Vyoo) are now available that uses genetic material from the pathogen to quickly (within hours) provide results. However, current practice has been to skip these tests altogether and directly prescribe broad-spectrum antibiotics to the patient. The proposed test has a greater advantage over so far proposed tests.
An 8 year old child was admitted to hospital with sepsis. The sample of blood was taken for bacteriological test (culture and antibiotic resistance). The hospital does not have a molecular laboratory. The standard antibiotic treatment with IV cefuroxime was introduced. After 70 min since antibiotic administration it was possible to obtain the first urine sample (in case of emergency when urine is not accessible it is possible to use blood serum or even saliva). The result was "probably positive", and because of the direct life threatening the test was repeated after 3 and 6 hrs of the first administration of an antibiotic, to confirm the result and monitor the efficiency of treatment as well. The above case is an example that results obtained in proposed tests are faster than all tests used so far, is simpler and cheaper.
The above test enables to detect antibiotic resistance even in case of an unknown mechanism.
Example 5 Co -infection Patient was treated with standard dose of penicillin because of gonorrhoea infection. The treatment was ineffective. The bacteriological swab was taken to evaluate its antibiotic resistance, the infectious factor was identified as Neisseria gonorrhoea penicillin (highly) susceptible. The conducted antibiotic resistance immunoenzymatic test was negative. Further investigation showed that patient was co-infected with Staphylococcus aureus which produced beta-lactamases which deactivated the given penicillins. This phenomenon also protected Neisseria gonorrhoea against penicillin. After other one course of an antibiotic, the patient recovered.
Example 6
Treatment monitoring/supervision A very important feature of the proposed antibiotic resistance diagnostic set based on the lateral flow test or lateral immunochromatographic assays is using it as a test for the efficiency of antibacterial treatment. It can be described by below example.
A patient who suffered from bacterial infection (infectious factor was penicillin resistant) apart from the other antibiotics, received a standard dose of amoxicillin 250 mg three times a day to monitor a treatment efficiency. When the given amoxicillin was detectable in the urine - it meant that infectious factor was eliminated from the organism.
The results of treatment with different antibiotics are showed in table 5. Table 6 shows (as comparison) tests CRP (C-reactive protein) and ESR (Erythrocyte Sedimentation Rate) used for monitoring the treatment efficiency.
Very important feature of the proposed antibiotic resistance diagnostic set, based on the lateral flow test or lateral immunochromatographic assays, which is used as a test for the efficiency of antibacterial treatment, is that the results are not on dependnt on the patient health condition. Sometimes patient's laboratory results (e.g. CRP or ESR) are fine, but patient is critically ill. His/her results are fine because the patient's liver is so damaged that is not able to produce all these compounds. The above test is an independent test which results directly correlated with treatment efficiency.
Table 5. Screening of the efficiency treatment (amoxicillin 250 mg three times a day) during treatment below given antibiotics:
Table 6. Comparison (collected data) of time of recovery to normal values of antibiotic resistance diagnostic test vs. CRP and ESR in case of successful bacterial treatment with antibiotics.
Example 7 Screening examination
Screening examination is aimed to detect asymptomatic carries of potentially pathogenic microorganisms, which produce penicillinase. The screening is extremely important in case of persons who are exposed on occupational injuries (e.g. firemen) - in case of broken bones the wound could be settled by pathogenic microorganisms, which could be very difficult to eradicate. The screening has an importance for patients who have artificial implants (e.g. artificial heart valves, etc.) because there is a risk of serious complications in case of colonisation by pathogenic organisms. The screening is very useful for patients who have to take the antibiotics as prevention against infection (e.g. in case of cystic fibrosis, after splenectomy, after tick bit - to prevent Lyme disease etc.), in such case early detection of beta-lactamase producing bacteria helps to change ineffective antibiotic prevention.
A simple test is proposed as screening test: patient takes a standard dose of 250 mg of amoxicillin and after 6 hrs a few drops of urine is put on the lateral flow test (or lateral immunochromatographic assays). In case of positive results (when the antibiotic is detected in urine) there is a proof of proper treatment, in case of negative result (when antibiotic is not detectable) the further examination should be done to find a source of potential infection.
Example 8
Antibiotic resistance detection of in case of cow's mastitis treatment.
Mastitis is the inflammation of the mammary gland. Mastitis is the most common and the most expensive disease of the cows. This disease and resulting infection can significantly reduce the amount and quality milk production. Mastitis is most commonly found in dairy herds. It is now recognised as a growing problem in beef herds, too. This is a growing problem in beef herds, and can result in weaning weights being reduced by 7% to 12.5%. The cost of one case of mastitis is about 370€. Different types of mastitis could concern from 30-80 % of the herd. Two types of mastitis (infectious and non-infectious) can occur. The vast majority (99%) of the cases is infectious. About 80-90% of all infections are caused by 3 types of bacteria: streptococci {Streptococcus agalactiae, Streptococcus dysgalactiae i Streptococcus uteris), staphylococci (e.g. Staphylococcus aureus and others,), and E. coli. Antibiotics are the main group of medications which are use in the treatment and prevention of mastitis. The efficiency of treatment is constanty decreasing (even new antibiotic generations are enter into treatment). The most important reason is that bacteria acquire resistance to widely used antibiotics. The veterinary guidelines recommend the bacterial culture with susceptibility (disk diffusion method) before treatment. Otherwise the treatment could be ineffective and a farmer would lose money because of long treatment and decreased milk production. The broad usage of the proposed new method detection of bacterial antibiotic resistance, diagnostic set based on the lateral flow test or lateral immunochromatographic assays to detect drug resistance of the contagious factor and application of detection of the drug and/or products of its/theirs degradations would bring a great efficiency in the treatment of mastitis. What could be illustrated by an example below:
Diagnosed mastitis was commenced with standard cloxacillin suspension, which was administered to an udder (500mg/10g). The drug was administered after udders' were disinfected with careful milking of the infected udder. During the next milking the milk sample was taken, the presence of antibiotic was detected what means the infectious factor is susceptible on administered antibiotic, and the therapy may be continued during the next three days in 24hrs intervals (to prevent recurrence of the disease). In case of negative result the antibiotic would have to be changed. The usage of the new lateral flow test or lateral immunochromatographic assays to detect antibiotic resistance
let to decreasing the cost, the given result is faster and lead to the short the pain of the animal.
The main difference among produced lateral flow tests (lateral immunochromatographic assays, quick tests, etc) for animals so far, is that all these test were used as test for detection the pollution of food (and other materials) with antibiotic. The proposed test (and method of detection antibiotic resistance) is developed, as device, which helps to detect if administered antibiotic, is efficient in given therapy. Another differences are different concentration, which these tests detect.
Claims
1. A method for determining bacterial antibiotic resistance or bacterial susceptibility, characterised in that, the drug resistance is detected by detection of the given antibiotic in the urine or other body fluids with the diagnostic set based on the lateral flow test or lateral immunochromatographic assays.
2. A method according to claim 1 characterised in that said antibiotic resistance is detected when concentration of a given antibiotic or its active metabolites is lower or equal than therapeutic concentration.
3. A method according to claim 1 characterised in that said antibiotic susceptibility is detected when concentration of a given antibiotic or its active metabolites is higher or equal to therapeutic concentration.
4. A method according to claim 1 characterised in that said method concerns human and/or animal organisms.
5. A method according to claim 1 characterised in that said method could be used as screening method of healthy organisms, which could be asymptomatic carriers of antibiotic resistant bacteria.
6. A diagnostic kit based on the lateral flow test or lateral immunochromatographic assays for the detection of the antibiotic resistance of the infective factor characterised in that said kit is a diagnostic assay contains a set of antibodies, preferably monoclonal antibodies, for detection of antibiotic resistance by detection of the presence of lack of the given antibiotic wherein said antibiotics are betalactams in biological fluids, especially in urine.
7. A diagnostic set according to claim 6 characterised in that said set is useful for screening healthy organisms or monitoring treatment efficiency.
8. Use of a diagnostic kit for detection of drug presence and/or its active metabolites by detection of its concentration in comparison to the therapeutic concentration in the body fluids with the lateral flow test or lateral immunochromatographic assays in screening and treatment of patients during antibiotic therapy to the antibiotic resistance detection in screening of the antibiotic resistance of the given antibiotic.
9. Use according to claim 8, in which antibiotic resistance is stated when concentration of a drug or/and its active metabolites is lower or equal than its therapeutic concentration.
10. Use according to claim 8, in which antibiotic susceptibility is, stated when concentration of a drug or/and its active metabolites are higher or equal to its therapeutic concentration.
11. Use according to claim 6, wherein said use concerns human and/or animal organisms.
12. Use according to claim 6, which concerns screening of healthy organisms, which could be asymptomatic carriers of antibiotic resistant bacteria.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL385415A PL385415A1 (en) | 2008-06-11 | 2008-06-11 | Method of bacterial resistance detection, diagnostic kit and application of the determination of presencea of the drug and/or products of its decomposition |
PLPL385415 | 2008-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009151346A1 true WO2009151346A1 (en) | 2009-12-17 |
Family
ID=39718147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/PL2009/000066 WO2009151346A1 (en) | 2008-06-11 | 2009-06-10 | A method for determining bacterial antibiotic resistance or bacterial susceptibility, a diagnostic kit for the detection of the antibiotic resistance and use of such diagnostic kit |
Country Status (3)
Country | Link |
---|---|
GB (1) | GB2460882A (en) |
PL (1) | PL385415A1 (en) |
WO (1) | WO2009151346A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102253216A (en) * | 2011-03-10 | 2011-11-23 | 北京维德维康生物技术有限公司 | Method, special kit and test paper strip for detecting beta-lactam antibiotics based on penicillin-binding protein |
CN103645273A (en) * | 2013-12-12 | 2014-03-19 | 佟雪梅 | Method and system for detecting drug resistance of beta-lactam antibiotics and application of beta-lactam antibiotics |
CN103713133A (en) * | 2012-09-29 | 2014-04-09 | 北京勤邦生物技术有限公司 | Test strip for detecting spiramycin, streptomycin, gentamycin and neomycin, and method |
WO2018106546A1 (en) * | 2016-12-06 | 2018-06-14 | Silver Lake Research Corporation | Methods of detection of antibiotic-resistant bacteria |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9597319B2 (en) * | 2014-04-23 | 2017-03-21 | Case Western Reserve University | Compositions and methods of inhibiting metallo-β-lactamases |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103536A (en) * | 1997-05-02 | 2000-08-15 | Silver Lake Research Corporation | Internally referenced competitive assays |
US20020192715A1 (en) * | 1998-06-25 | 2002-12-19 | Jacques Degelaen | Test kit for determining process for determining antibiotics containing a beta-lactam ring in a biological fluid |
CN200982971Y (en) * | 2005-04-15 | 2007-11-28 | 华南农业大学 | Penicillin quick half quantitative detection test paper |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9009692D0 (en) * | 1990-04-30 | 1990-06-20 | Ucb Bioproducts | An enzymatic method of determining beta-lactam ring antibiotics |
EP0593112B1 (en) * | 1992-10-06 | 1998-08-26 | Gist-Brocades N.V. | Detection of antibiotics |
-
2008
- 2008-06-11 PL PL385415A patent/PL385415A1/en not_active Application Discontinuation
- 2008-07-08 GB GB0812469A patent/GB2460882A/en not_active Withdrawn
-
2009
- 2009-06-10 WO PCT/PL2009/000066 patent/WO2009151346A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103536A (en) * | 1997-05-02 | 2000-08-15 | Silver Lake Research Corporation | Internally referenced competitive assays |
US20020192715A1 (en) * | 1998-06-25 | 2002-12-19 | Jacques Degelaen | Test kit for determining process for determining antibiotics containing a beta-lactam ring in a biological fluid |
CN200982971Y (en) * | 2005-04-15 | 2007-11-28 | 华南农业大学 | Penicillin quick half quantitative detection test paper |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102253216A (en) * | 2011-03-10 | 2011-11-23 | 北京维德维康生物技术有限公司 | Method, special kit and test paper strip for detecting beta-lactam antibiotics based on penicillin-binding protein |
CN103713133A (en) * | 2012-09-29 | 2014-04-09 | 北京勤邦生物技术有限公司 | Test strip for detecting spiramycin, streptomycin, gentamycin and neomycin, and method |
CN103645273A (en) * | 2013-12-12 | 2014-03-19 | 佟雪梅 | Method and system for detecting drug resistance of beta-lactam antibiotics and application of beta-lactam antibiotics |
CN103645273B (en) * | 2013-12-12 | 2015-12-30 | 宁波诺威医疗器械有限公司 | The detection method of beta-lactam antibiotic drug resistance, system and application thereof |
WO2018106546A1 (en) * | 2016-12-06 | 2018-06-14 | Silver Lake Research Corporation | Methods of detection of antibiotic-resistant bacteria |
Also Published As
Publication number | Publication date |
---|---|
GB2460882A (en) | 2009-12-16 |
GB0812469D0 (en) | 2008-08-13 |
PL385415A1 (en) | 2009-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bryant et al. | β-Lactamase activity in human pus | |
Bryant et al. | Interaction of purulent material with antibiotics used to treat Pseudomonas infections | |
CN101790683B (en) | Compositions and means for diagnosing microbial infections | |
Alshaalan et al. | Brucellosis in children: Prevention, diagnosis and management guidelines for general pediatricians endorsed by the Saudi Pediatric Infectious Diseases Society (SPIDS) | |
CA1340780C (en) | Method of detecting bacteria in urine | |
WO2009151346A1 (en) | A method for determining bacterial antibiotic resistance or bacterial susceptibility, a diagnostic kit for the detection of the antibiotic resistance and use of such diagnostic kit | |
Yehia et al. | Prevalence of methicillin-resistant (mecA gene) and heat-resistant Staphylococcus aureus strains in pasteurized camel milk | |
Kuriyama et al. | Antimicrobial chemotherapy: significance to healthcare | |
Jain et al. | Escherichia vulneris: an unusual cause of complicated diarrhoea and sepsis in an infant. A case report and review of literature | |
Jauregui et al. | Cefepime as treatment for osteomyelitis and other severe bacterial infections | |
Doone et al. | Risk factors for penicillin-resistant systemic pneumococcal infections in children | |
US20090123960A1 (en) | Method for Removing Antibiotics From Blood Culture Samples | |
US20140228248A1 (en) | Methods and compositions for detecting infections | |
Barber et al. | Antibiotic sensitivity of Proteus species | |
En et al. | Pediatric brain abscess with fatal outcome caused by hypervirulent Klebsiella pneumoniae, serotype K2-ST65 | |
Isozaki et al. | A case of urinary tract infection caused by Kluyvera ascorbata in an infant: case report and review of the literature | |
Pal et al. | Rat Bite Fever: An Infectious Under Reported Bacterial Zoonotic Disease | |
Boothe | Interpreting culture and susceptibility data in critical care: perks and pitfalls | |
Mohanty et al. | Urinary tract infection due to Aeromonas species: An uncommon causative agent | |
Sabah et al. | Immunological parameters examination of the oral fluid in normal and pathological conditions: sensitivity analysis of microorganisms in modern therapeutic practice in vitro | |
Poindexter et al. | Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections | |
Matsiota-Bernard et al. | Use of the Polymerase Chain Reaction for the Detection | |
Alipour et al. | Prevalence of CTX-M, OXA and KPC genes in Klebsiella pneumoniae isolates obtained from patients | |
Hodges et al. | Carbenicillin indanyl sodium oral therapy of urinary tract infections | |
WO2023164613A2 (en) | Methods for diagnosing and/or treating otitis media |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09762727 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09762727 Country of ref document: EP Kind code of ref document: A1 |